Otometrics Launches Aurical® IQ – Delivering the First and Only Guided Workflow Enabling up to 51% Faster Fittings and 39% Improved Workflow Accuracy
14.10.2026 09:00:00 CEST | Business Wire | Press release
Clinical evaluations demonstrated up to 51% faster fitting times for experienced clinicians and 39% improved workflow accuracy for newer clinicians; Aurical IQ also supports the NAL-NL3 Fitting System
Otometrics, the Hearing & Balance division of Natus Sensory, today announced Aurical® IQ, the next generation of its trusted hearing aid fitting and verification platform. Combining the first and only Guided Workflow for hearing aid fitting and verification, support for the NAL-NL3 Fitting System and a redesigned Otosuite® software experience, Aurical IQ is designed to help hearing care professionals work more efficiently and follow best-practice fitting procedures with greater consistency.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014023398/en/
Aurical IQ
Guided Workflow provides structured, step-by-step guidance through the fitting and verification process, designed to make best-practice fitting easier to follow.
A new chapter of innovation for Otometrics
Clinical evaluations demonstrated measurable benefits for clinicians at different levels of experience. Experienced clinicians achieved up to 51% faster fitting times using Guided Workflow compared with Aurical’s classic workflow.* For newer clinicians, Guided Workflow improved workflow accuracy by 39%.**
“Aurical IQ represents a new chapter of innovation for Otometrics,” said Peter Reimer, CEO, Natus Sensory. “We are building on decades of trusted hearing care expertise with solutions that address the real needs of clinicians today while preparing for what comes next. Aurical IQ is part of a broader wave of innovation across Otometrics, reflecting the renewed momentum in the business and our commitment to delivering meaningful innovation for hearing care professionals.”
For Otometrics, Aurical IQ is about bringing meaningful innovation into everyday clinical practice,” said Carsten Kind, Business Unit Leader, Otometrics, Natus Sensory. “It is also an important first step in how we want to move the business forward: with focused innovation that is practical, clinically relevant and built around how hearing care professionals work. We are building on a trusted Aurical platform, while creating a stronger foundation for future automation and AI-enabled capabilities.
Bringing NAL-NL3 into the fitting workflow
Aurical IQ also supports the NAL-NL3 Fitting System, the latest generation of the National Acoustic Laboratories’ hearing aid prescription system.
NAL-NL3 builds on decades of NAL research and introduces new capabilities designed to support contemporary hearing aid fitting, including the core NAL-NL3 Prescription and Modules addressing specific fitting requirements.
“NAL is pleased to see the NAL-NL3 Fitting System, with the core Prescription and Modules for special use cases, integrated into the latest release from Otometrics,” said Brent Edwards, Managing Director, National Acoustic Laboratories. “We are proud to collaborate with fellow innovative technology leaders such as Otometrics to bring impactful technologies to hearing care professionals, enabling improved care and better outcomes for people with hearing difficulties.”
Ready for tomorrow
Aurical IQ brings together the trusted fitting and verification capabilities of Aurical with a redesigned software experience and a platform created to support continued innovation.
Alongside Guided Workflow and NAL-NL3, Aurical IQ provides real-ear verification, binaural and wireless REM capabilities, refreshed Aurical hardware and longer probe leads designed to provide greater flexibility in complex fitting situations. Its re-engineered software foundation is designed to evolve as clinical workflows, fitting standards and connectivity develop, creating a foundation for further automation and future AI-powered capabilities.
Aurical IQ will be officially introduced at EUHA 2026 in Hanover, Germany, where hearing care professionals can experience Guided Workflow and the new Aurical IQ platform firsthand at the Otometrics booth, #514.
About Otometrics
Meaningful moments in life begin with a sense – a sound, a movement, a connection to the world around us. That belief guides everything we do at Otometrics.
Otometrics is the Hearing & Balance division of Natus Sensory, supporting clinicians worldwide with trusted solutions for hearing assessment, hearing aid fitting and verification, tympanometry, balance assessment and digital ear scanning. Our portfolio includes Aurical®, Madsen®, Otoscan®, ICS® and Bio-logic®, supporting hearing and balance professionals across the patient journey.
Built on decades of hearing and balance expertise, we develop intuitive, reliable solutions grounded in real-world clinical needs – helping clinicians work with greater confidence and efficiency today while advancing the future of hearing and balance care.
Natus Sensory is an ARCHIMED company since 2022. Learn more on our website Home - Natus Sensory.
About ARCHIMED
With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Services, and MedTech. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages $15 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation. ARCHIMED - Impacting Healthcare
* In an experienced clinician workflow comparison study, users demonstrated up to 51% faster fitting times with Guided Workflow compared with the Classic Workflow.
** In a newer clinician onboarding evaluation study, the Guided Workflow improved workflow accuracy by reducing errors by 39%
View source version on businesswire.com: https://www.businesswire.com/news/home/20261014023398/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Debiopharm’s Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistance14.10.2026 14:00:00 CEST | Press release
Despite the remarkable progress made by ADCs, many cancer patients continue to face disease progression due to treatment resistance, tumor heterogeneity, and dose-limiting toxicities At World ADC 2026 San Diego, Debiopharm presented their latest ADC innovation to overcome these challenges with novel linker-payload technology, including modular dual payload linker MLINK DUO and modular cathepsin B-cleavable linker MLINK Select Research results with various MultiLINKTM Linker Technologies showcased broadening of vedotin-based ADC therapeutic index for MLINK Select ADCs, synergistic antitumor activity with MLINK Duo, and homogeneous DAR8 conjugation with MLINK HiSol Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced their latest research on antibody drug conjugate (ADC) research released at World ADC San Diego 2026. Results highlighted the pre-cli
Responsible AI for Children: IEEE Delivers a Trusted Safety Formula to Help Protect Kids Online14.10.2026 14:00:00 CEST | Press release
With children’s AI exposure surging, IEEE Standards Association certification helps ensure AI products for kids are ethically designed, independently tested and continually accountable for safety and well-beingFirst product certification issued to educational platform from Greek National Centre for Scientific Research The IEEE Standards Association, the global, consensus-building standards development organization of IEEE – the world’s largest technical professional organization and public charity dedicated to advancing technology for the benefit of humanity – today advanced its Responsible AI for Children (RAIC) Certification Program with the first product certified for children’s online safety. As children increasingly engage with digital and AI-enabled technologies, parents, educators, developers, and regulators want tools they can trust. IEEE’s Responsible AI for Children (RAIC) certification directly addresses these needs by translating global technical standards into a practical
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 202614.10.2026 14:00:00 CEST | Press release
− TAK-881 met its primary endpoint, demonstrating pharmacokinetic comparability to HYQVIA® in patients 16 years and older − TAK-881 may shorten infusion times and offer the opportunity for fewer required infusion sites compared to HYQVIA with 50% less volume while maintaining up to once-monthly dosing − Adult infection outcomes and safety and tolerability profiles were comparable to HYQVIA based on descriptive analyses and consistent with established IG therapy standards Takeda (TSE:4502/NYSE:TAK) announced detailed results from the pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001) evaluating investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) and Recombinant Human Hyaluronidase], which, if approved, has the potential to become the first facilitated SCIG 20% therapy for patients with Primary Immunodeficiency Disease (PID) administered up to once-monthly (every 3 to 4 weeks). Data in participants aged 16 years and older are featured in two late-b
Datavault AI Appoints Shareholder and Investment Executive Jeffrey Tirman to the Boardof Directors14.10.2026 13:55:00 CEST | Press release
Tirman, through his family office Abri Capital Ltd., holds 26 million DVLT shares and brings over 35 years of international investment management and corporate restructuring experience to the Company Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced the appointment of Jeffrey Tirman to its Board of Directors, effective as of October 12, 2026. Mr. Tirman was designated by NYIAX, Inc. (“NYIAX”) in connection with Datavault AI's recently completed acquisition of NYIAX, and he previously served on NYIAX's board of directors. As a Datavault AI Shareholder, Mr. Tirman brings both an ownership perspective and extensive management experience to the Board. Mr. Tirman has more than 35 years of international investment management experience, focused on corporate transformation, capital strategy and value creation. He has led c
EZO Reaches Financial Close on €150 Million Senior Debt Facility14.10.2026 13:21:00 CEST | Press release
Investment-grade, non-recourse financing will support the delivery of more than 3,000 charge points primarily across the whole of the UK along with additional development in Ireland. EZO has reached financial close on a €150 million investment-grade, non-recourse, senior debt facility. The funding will finance the design, installation, operation and maintenance of over 3,000 charge points, representing over 100,000 kWs of capacity, across the UK and Ireland under mostly long-term public sector “PPP-like” concessions with an attractive risk allocation between the public and private sector that will significantly advance EV infrastructure delivery, on time and to budget. These charge points are estimated to generate well in excess of £1 billion in electricity sales over the next 20 years, a portion of which will be shared with the public sector while, at the end of the concession, the chargers will revert back to the public sector. Headquartered in Ireland, EZO has expanded rapidly into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom